港股详情

本页面由Tiger Trade Technology Pte. Ltd.提供服务

医美概念股

1,052.864

-27.807-2.57%

涨家数：- -

跌家数：11

平家数：2

市盈率：- -

高：1,097.798

开：1,080.672

低：1,046.950

收：1,080.672

成交量：4,704.44万

成交额：5.83亿

市值：1,743.26亿

流通市值：1,302.51亿

数据加载中...

总览新闻资讯

四环医药(00460)出现大手买入130万股，成交价$1.28，涉资166.4万

阿斯达克财经

【券商聚焦】中信建投：医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会

复星医药2025年报：收入417亿，净利增速21.7%，创新药与境外收入占比同步提升

四环医药(00460)出现大手买入130万股，成交价$1.32，涉资171.6万

阿斯达克财经

复星医药盘中涨超5% 去年纯利同比增长21.69%至33.71亿元

复星医药(02196)拟派发末期股息每股0.39元

丽丰控股(01125)公布中期业绩公司拥有人应占净亏损3.84亿港元同比增长1.34倍

复星医药(02196)控股子公司拟新增开展融资租赁业务

复星医药：关于2026年续聘会计师事务所的公告

中国复星医药去年净利同比增超两成，创新药收入与境外收入占比均提升

复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展

轩竹生物-B(02575)涨逾8% 安久卫治疗反流性食管炎III期试验完成全部受试者入组

【券商聚焦】中信证券：GDF-15阻断剂有望在未来获批治疗肿瘤恶病质

《业绩》复锐医疗科技(01696.HK)全年纯利1,902万美元跌24.3% 末期息派9.5港仙

阿斯达克财经

复锐医疗科技2025年业绩实现稳健增长

复锐医疗科技(01696)发布年度业绩股东应占溢利1901.6万美元同比减少24.32%

昊海生物科技(06826)3月23日耗资约240.55万港元回购10.72万股

四环医药(00460)出现大手卖出120万股，成交价$1.27，涉资152.4万

阿斯达克财经

医思健康(02138)股价下跌5%，现价港币$0.475

阿斯达克财经

【券商聚焦】交银国际：CXO行情持续回暖料板块估值倍数合理

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/BK1593/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":1052.8644,"timestamp":1774512495612,"preClose":1080.6718,"halted":0,"volume":47044383,"delay":0,"changeRate":-0.025732,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盘","change":-27.807373,"latestTime":"03-26 16:00:00","open":1080.6718,"high":1097.7981,"low":1046.9497,"amount":582544096,"amplitude":0.047053,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1774575000000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":1.554461,"peRate":23.844152,"turnoverRate":0.002285,"increases":0,"decrements":11,"flats":2,"marketCap":174326077576,"floatMarketCap":130251360456},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1097.7981,"amplitude":0.047053,"preClose":1080.6718,"low":1046.9497,"pbRate":"1.554461","latestPrice":1052.8644,"volume":47044383,"delay":0,"open":1080.6718,"prevYearClose":1094.978,"prevWeekClose":1084.158,"prevMonthClose":1133.252,"prevQuarterClose":1094.978,"fiveDayClose":1101.872,"twentyDayClose":1118.873,"sixtyDayClose":1143.453,"secType":"PLATE","market":"HK","turnoverRate":0.002285,"peRate":23.844152,"marketCap":174326077576,"floatMarketCap":130251360456,"timestamp":1774512495612,"nameCN":"医美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":0,"down":11,"flat":2},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2622329938","title":"四环医药(00460)出现大手买入130万股，成交价$1.28，涉资166.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622329938","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622329938?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 15:50","pubTimestamp":1774511400,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:50出现大手买入，成交量为130万，成交价为港币$1.28，涉资166.4万。至目前为止，股价跌3.03%，今日最高价为$1.34，而最低价为$1.28，总成交量为1.774千万股，总成交金额港币$2.306千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145554547_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603266608/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603266608/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1191","BK1593","BK1515","BK1600","00460"],"gpt_icon":0},{"id":"2622818008","title":"【券商聚焦】中信建投：医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818008","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622818008?lang=zh_cn&edition=fundamental","pubTime":"2026-03-26 09:18","pubTimestamp":1774487918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1574","601066","BK1571","BK1591","09997","BK1584","BK1502","BK1583","LU0173614495.USD","159883","01066","01302","BK1615","BK1142","BK1100","09996","BK1610","BK1600","02190","BK1222","02235","BK1515","BK1589","BK1585","BK1617","LU0287142896.SGD","BK1247","02252","BK1587","BK1501","BK1189","00853","BK1161","00241","BK0276"],"gpt_icon":0},{"id":"2622074818","title":"复星医药2025年报：收入417亿，净利增速21.7%，创新药与境外收入占比同步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074818","media":"IPO早知道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074818?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445520,"startTime":"0","endTime":"0","summary":"报告期内，经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，增长主要系对外授权收入增加所致。创新药管线：研发投入转向商业兑现的效率提升复星医药2025年研发总投入达59.13亿元，同比增长6.46%，其中创新药品相关研发投入43.03亿元，同比大增15.98%，占研发总投入的72.77%，占比同比提升5.97个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-25/doc-inhsfmmn0790711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK0183","BK0028","BK0096","BK0175","02196","BK1515","BK1161","BK0196","600196","BK0012","BK1574","BK1191","BK0239","BK0187","BK0060","159992","BK1593","BK0188"],"gpt_icon":0},{"id":"2622236460","title":"四环医药(00460)出现大手买入130万股，成交价$1.32，涉资171.6万","url":"https://stock-news.laohu8.com/highlight/detail?id=2622236460","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622236460?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 15:40","pubTimestamp":1774424400,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午03:40出现大手买入，成交量为130万，成交价为港币$1.32，涉资171.6万。至目前为止，股价无升跌，今日最高价为$1.34，而最低价为$1.3，总成交量为2.808千万股，总成交金额港币$3.707千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603258254/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603258254/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1600","BK1191","BK1593","00460","BK1515"],"gpt_icon":0},{"id":"2622845045","title":"复星医药盘中涨超5% 去年纯利同比增长21.69%至33.71亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622845045","media":"新浪港股","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622845045?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 10:54","pubTimestamp":1774407240,"startTime":"0","endTime":"0","summary":"　　复星医药盘中涨超5%，截至发稿，股价上涨3.84%，现报18.93港元，成交额2494.07万港元。　　3月24日晚，复星医药发布2025年度业绩，该集团取得营业收入人民币416.62亿元，同比增加1.45%；归属于上市公司股东的净利润33.71亿元，同比增加21.69%；基本每股收益1.27元，拟每10股派发现金红利3.90元（税前）。　　报告期内，集团创新药品实现收入98.93亿元，同比增长29.59%，占制药业务收入比重提升至33.16%，较上年提高6.77个百分点。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-25/doc-inhseiye3701176.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0187","600196","BK0175","BK1593","BK1515","BK0183","BK0188","02196","BK0012","BK0096","BK0239","BK1191","BK0196","BK0028","BK0060"],"gpt_icon":0},{"id":"2622401171","title":"复星医药(02196)拟派发末期股息每股0.39元","url":"https://stock-news.laohu8.com/highlight/detail?id=2622401171","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622401171?lang=zh_cn&edition=fundamental","pubTime":"2026-03-25 07:34","pubTimestamp":1774395268,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，该公司拟派发末期股息每股0.39元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418426.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["600196","BK0175","BK0188","BK4585","VIG","BK0187","BK1515","BK0012","BK0028","02196","BK0060","BK0096","BK1191","BK1593","BK4588","BK0239","BK0183","BK0196"],"gpt_icon":0},{"id":"2621093847","title":"丽丰控股(01125)公布中期业绩 公司拥有人应占净亏损3.84亿港元 同比增长1.34倍","url":"https://stock-news.laohu8.com/highlight/detail?id=2621093847","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621093847?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 22:12","pubTimestamp":1774361556,"startTime":"0","endTime":"0","summary":"智通财经APP讯，丽丰控股(01125)公布截至2026年1月31日止6个月中期业绩，营业额约9.27亿港元，同比增长43.1%;公司拥有人应占净亏损3.84亿港元，同比增长1.34倍;每股亏损1.16港元。公告称，亏损增长主要由于于回顾期间内出售横琴创新方第二期的一幢住房大楼(T1)及撇减横琴创新方第二期的物业(主要为T3)而产生的亏损。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418327.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":"丽丰控股(01125)公布中期业绩 公司拥有人应占净亏损3.84亿港元 同比增长1.34倍","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","01125","BK1240"],"gpt_icon":0},{"id":"2621067566","title":"复星医药(02196)控股子公司拟新增开展融资租赁业务","url":"https://stock-news.laohu8.com/highlight/detail?id=2621067566","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621067566?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 20:53","pubTimestamp":1774356801,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复星医药(02196)发布公告，为进一步拓宽融资渠道，公司部分控股子公司拟与具备相应资质的融资租赁公司/金融租赁公司新增开展融资租赁业务，融资总额不超过人民币6.5亿元，包括：(1)以部分自有资产设备作为转让标的及租赁物开展售后回租、(2)以新购资产设备直租。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418258.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0188","BK0196","BK1191","BK1593","BK0060","BK0096","BK0239","BK0012","02196","BK0175","BK1515","BK0028","BK0187","BK0183","600196"],"gpt_icon":0},{"id":"2621757062","title":"复星医药：关于2026年续聘会计师事务所的公告","url":"https://stock-news.laohu8.com/highlight/detail?id=2621757062","media":"证券日报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621757062?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 20:25","pubTimestamp":1774355100,"startTime":"0","endTime":"0","summary":"证券日报网讯3月24日，复星医药发布公告称，2026年3月24日，公司第十届董事会第二十五次会议审议通过了关于本公司2026年续聘会计师事务所及2025年会计师事务所报酬的议案，拟续聘安永华明会计师事务所（特殊普通合伙）为本公司2026年度境内财务报告和内部控制审计机构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603243682800769.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK0183","BK0060","BK0175","BK1593","BK1191","BK0196","600196","BK0028","02196","BK0187","BK0096","BK0012","BK0239","BK0188","BK1515"],"gpt_icon":0},{"id":"2621162069","title":"中国复星医药去年净利同比增超两成，创新药收入与境外收入占比均提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2621162069","media":"路透中文","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621162069?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 19:21","pubTimestamp":1774351293,"startTime":"0","endTime":"0","summary":"路透北京3月24日 - 中国“复星系”医药及疫苗巨头--复星医药600196.SS2196.HK周二公布，去年营收同比微升，净利润则大增逾两成；公司称创新驱动与国际化成效逐步显现，创新药品收入占比与境外收入占比的同步提升。复星医药发布在上交所的财报称，2025年创新药品收入占制药业务收入比重、境外业务收入占营业收入比重双双提升至30%以上。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"37684715aaf54a73b9fe52ee56a263cc","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260324:nL4T40C097:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0028","BK0239","BK1191","600196","BK1593","BK0060","00656","BK0175","02196","BK0187","BK0096","BK0012","BK0196","BK1515","BK0183","BK0188","BK1230"],"gpt_icon":0},{"id":"2621069488","title":"复星医药(02196)发布2025年报：创新药和全球化双引擎驱动高质量发展","url":"https://stock-news.laohu8.com/highlight/detail?id=2621069488","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621069488?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 19:16","pubTimestamp":1774350963,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，复星医药(600196.SH，02196)公布2025年度经营业绩。复星医药以创新研发突破与全球化体系升级为双引擎，实现营业收入人民币416.62亿元，同比增长1.45%，其中，创新药品收入98.93亿元，同比增长29.59%;境外收入129.77亿元，同比增长14.87%，两大核心指标实现双增长，深化复星医药高质量发展的底层逻辑。归母净利润33.71亿元，同比增长21.69%;归母扣非净利润23.40亿元，同比增长1.12%;经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，高质量发展底座进一步夯实。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418167.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0060","BK1191","159992","BK1515","BK1593","BK0188","BK1574","BK0096","06978","BK0187","BK0028","02196","BK0196","BK0012","BK0239","BK0183","BK0175","600196"],"gpt_icon":0},{"id":"2621603174","title":"轩竹生物-B(02575)涨逾8% 安久卫治疗反流性食管炎III期试验完成全部受试者入组","url":"https://stock-news.laohu8.com/highlight/detail?id=2621603174","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621603174?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 10:10","pubTimestamp":1774318245,"startTime":"0","endTime":"0","summary":"消息面上，四环医药发布公告，公司旗下非全资附属公司轩竹生物科技股份有限公司的创新药安奈拉唑钠肠溶片用于治疗成人反流性食管炎的中国III期临床试验已顺利完成全部500名受试者入组。据悉，安奈拉唑钠肠溶片于2023年6月获得中国国家药品监督管理局批准上市，用于患者治疗十二指肠溃疡。此次III期临床研究于2025年7月全面展开，近期完成受试者入组，标志着本公司在创新药物研发方面取得了重要进展。","market":"hk","thumbnail":"https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/YjNiOTNjODIxNjM4MTUzMTI5MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977089","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1593","BK1515","02575","BK1600","BK1191","00460","III","BK4134"],"gpt_icon":0},{"id":"2621052036","title":"【券商聚焦】中信证券：GDF-15阻断剂有望在未来获批治疗肿瘤恶病质","url":"https://stock-news.laohu8.com/highlight/detail?id=2621052036","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621052036?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 09:01","pubTimestamp":1774314061,"startTime":"0","endTime":"0","summary":"目前GDF-15阻断剂行业处于临床开发阶段，尚无任何药物获批，多数临床管线处于早期阶段，进度最快的为辉瑞公司和CatalYm公司。鉴于Ponsegromab在II期临床试验中的优异结果以及Ponsegromab的II/III期临床试验设计，该机构认为其有望获批治疗肿瘤恶病质，成为GDF-15阻断剂上市后第一个适应症。后续如果Ponsegromab成功上市以及Visugromab读出积极数据，将催化GDF-15阻断剂市场快速增长。","market":"us","thumbnail":"https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/MTU3MGM5Y2M3ZDk5Mjg2ODIwNjM2NDU0OA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977070","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK0012","BK1593","LU0348783233.USD","09688","LU1303224171.USD","BK1574","LU1064131003.USD","BK1515","02228","LU0405327148.USD","LU2289578879.USD","02367","06160","BK1585","BK1191","LU1997245094.SGD","LU2328871848.SGD","BK1161","BK1147","LU1580142542.USD","BK1207","600030","IE00B543WZ88.USD","LU1781817850.SGD","03933","LU0640798160.USD","06030","01530","BK1564","LU1794554557.SGD","01099","SG9999014674.SGD","LU0348735423.USD","LU1655091616.SGD","LU0307460666.USD","02268","LU0405327494.USD","06821","BK0276","BK1141","09926","LU1328615791.USD","HK0000165453.HKD","LU0417516902.SGD","IE00BPRC5H50.USD","01789","LU1255011170.USD","BK0028","02196","LU0348825331.USD"],"gpt_icon":0},{"id":"2621088538","title":"《业绩》复锐医疗科技(01696.HK)全年纯利1,902万美元跌24.3%  末期息派9.5港仙","url":"https://stock-news.laohu8.com/highlight/detail?id=2621088538","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621088538?lang=zh_cn&edition=fundamental","pubTime":"2026-03-24 00:44","pubTimestamp":1774284240,"startTime":"0","endTime":"0","summary":"复锐医疗科技(01696.HK) 公布2025年度业绩，收益3.65亿美元，按年增加4.7%。录得纯利1,902万美元，倒退24.3%，每股盈利4.06美仙。末期息派9.5港仙。(de/d)(港股报价延迟最少十五分钟。)过往派息公布日期派息事项派息内容2025/08/20中期业绩无派息2025/03/19末期业绩股息：港元 0.12602024/08/21中期业绩无派息2024/03/20末期业绩股息：港元 0.1580AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20190704152928340_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20190704152928340_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511622/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1511622/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1100","BK1593","01696","BK1585"],"gpt_icon":0},{"id":"2621744085","title":"复锐医疗科技2025年业绩实现稳健增长","url":"https://stock-news.laohu8.com/highlight/detail?id=2621744085","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621744085?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 22:55","pubTimestamp":1774277700,"startTime":"0","endTime":"0","summary":"注射填充业务收入为28.0百万美元，较2024年同比增长185.6%。经调整净利润为31.0百万美元，较2024年的28.7百万美元同比增长7.9%。经调整净利润率为8.5%，2024年同期为8.2%。\" 复锐医疗科技首席执行官Eyal Ben David先生表示：\"2025年是复锐医疗科技夯实下一阶段增长根基的关键之年。\" 复锐医疗科技联席首席执行官兼首席财务官李家宏先生表示：\"2025年，复锐医疗科技积极应对外部挑战，有序推进各项战略部署，财务表现稳健向好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4916393_ZH16393_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1593","BK1585","BK1100","01696"],"gpt_icon":0},{"id":"2621896702","title":"复锐医疗科技(01696)发布年度业绩 股东应占溢利1901.6万美元 同比减少24.32%","url":"https://stock-news.laohu8.com/highlight/detail?id=2621896702","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621896702?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 22:38","pubTimestamp":1774276690,"startTime":"0","endTime":"0","summary":"智通财经APP讯，复锐医疗科技(01696)发布截至2025年12月31日止年度业绩，该集团期内取得收益3.65亿美元，同比增加4.7%;母公司拥有人应占溢利1901.6万美元，同比减少24.32%;每股基本盈利4.06美仙;拟派发末期股息每股0.095港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417697.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1100","BK1585","BK1593","01696"],"gpt_icon":0},{"id":"2621501771","title":"昊海生物科技(06826)3月23日耗资约240.55万港元回购10.72万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2621501771","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621501771?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 17:32","pubTimestamp":1774258365,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)公布，2026年3月23日耗资约240.55万港元回购10.72万股股份。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1417421.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06826","BK1161","BK1593"],"gpt_icon":0},{"id":"2621172068","title":"四环医药(00460)出现大手卖出120万股，成交价$1.27，涉资152.4万","url":"https://stock-news.laohu8.com/highlight/detail?id=2621172068","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621172068?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 14:55","pubTimestamp":1774248900,"startTime":"0","endTime":"0","summary":"[大手成交]四环医药(00460)在下午02:55出现大手卖出，成交量为120万，成交价为港币$1.27，涉资152.4万。至目前为止，股价跌7.971%，今日最高价为$1.38，而最低价为$1.27，总成交量为2.646千万股，总成交金额港币$3.447千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180815142908460_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603239487/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAV2603239487/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1515","BK1593","BK1191","00460","BK1600"],"gpt_icon":0},{"id":"2621724466","title":"医思健康(02138)股价下跌5%，现价港币$0.475","url":"https://stock-news.laohu8.com/highlight/detail?id=2621724466","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621724466?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 13:30","pubTimestamp":1774243800,"startTime":"0","endTime":"0","summary":"[下跌股]医思健康(02138) 股价在下午01:30比前收市价下跌5%，现股价为港币$0.475。至目前为止，今日最高价为$0.51，而最低价为$0.475。总成交量为126.3万股，总成交金额为港币$62.254万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152743541_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603236510/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2603236510/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1215","BK1511","BK1593","02138"],"gpt_icon":0},{"id":"2621095723","title":"【券商聚焦】交银国际：CXO行情持续回暖 料板块估值倍数合理","url":"https://stock-news.laohu8.com/highlight/detail?id=2621095723","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2621095723?lang=zh_cn&edition=fundamental","pubTime":"2026-03-23 10:25","pubTimestamp":1774232735,"startTime":"0","endTime":"0","summary":"金吾财讯 | 交银国际表示，多重利好因素共振下，2025年以来CXO行情持续回暖。该机构建议重点关注标的细分赛道成长力、核心能力布局、盈利和订单增长能见度、地缘风险敞口及估值上升空间。基于此，该机构首推药明合联，首次覆盖并重点推荐凯莱英和康龙化成。","market":"other","thumbnail":"https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ZDQ3YWRiNzU2MjI5OWUwYTllMmZlMTAyNzEyNzQzMTU2MQ==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977006","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BPRC5H50.USD","LU2476274720.SGD","02268","BK1583","09688","BK1617","BK1585","LU0634319403.HKD","LU0417516738.SGD","02196","BK1500","LU0307460666.USD","LU0348767384.USD","LU2488822045.USD","LU2399975544.HKD","BK1593","BK1141","02228","BK1207","LU1115378108.SGD","BK1191","LU0417516571.SGD","02367","LU2476274308.USD","03933","LU1770034418.SGD","03329","01789","IE00B543WZ88.USD","BK1574","BK1161","LU2778985437.USD","BK1588","BK1197","LU0348766576.USD","LU1719994722.HKD","06821","09926","LU1794554557.SGD","01099","LU0348784397.USD","LU0348827113.USD","LU0348735423.USD","LU0540923850.HKD","LU0417516902.SGD","LU1303224171.USD","LU2328871848.SGD","CXO","06160","01530"],"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":1,"totalSize":59,"code":"91000000","status":"200"}]}}